Project Grant R01DA054145

Award Date 7/1/24
Completion Date 4/30/29
Dollars Obligated $2.3M
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This $2,118,992 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a longitudinal study investigating the neural and psychiatric consequences of cannabis use in depressed adolescents. The research aims to prospectively examine the effects of cannabis, the most widely used illicit drug among teenagers, on reward and pain neurocircuits in adolescents with depression. The study will evaluate 250...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding a $621,186 longitudinal study to examine the impact of circulating endocannabinoid levels on neurocognition, impulsivity, and early cannabis use patterns in youth enrolled in the Adolescent Brain Cognitive Development (ABCD) study. The 5-year study, running from July 2025 to March 2030, will be conducted by the University of...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a 5-year, $2,726,432 research study on co-use of cannabis and prescription opioids among emerging adults in medical settings. The study will enroll emerging adults aged 18-25 who either have no history of cannabis use or have used cannabis in the past month and are prescribed an opioid for acute pain management. Participants will be followed...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, aims to study the effects of cannabis use on treatment outcomes for adolescents with alcohol use disorder (AUD) and co-occurring psychiatric disorders (CODs) in community-based treatment settings. The $197,262 award will leverage mixed methods, including qualitative interviews, an ecological momentary assessment pilot, and...
The National Institute on Drug Abuse (NIDA) awarded a $445,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The grant will fund the development and pilot testing of a novel telehealth and mobile health intervention called MOMENT-V to address cannabis use disorder in young adults seen in primary care. The intervention combines motivational enhancement therapy delivered via...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $450,313 to Trustees of Dartmouth College to conduct research on the impact of psychotherapeutic advertising claims and mental health warning labels on online cannabis purchasing behaviors among individuals with symptoms of depression and/or anxiety. The study aims to investigate whether psychotherapeutic advertising claims increase cannabis...
This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) to the Cambridge Public Health Commission, doing business as the Cambridge Health Alliance, will provide $177,110 to study the impact of cannabis legalization and commercialization on substance use and mental health outcomes among individuals with psychosis. The research will utilize quasi-experimental difference-in-difference methods to analyze data from the Population...
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $197,640 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a pilot randomized controlled trial of a digital therapeutic called AMP-C. The goal of AMP-C is to address the co-occurring conditions of cannabis use disorder (CUD) and major depressive disorder (MDD) by targeting reward dysfunction, a...
This $311,000 federal Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop and pilot test a mobile-enhanced, web-based intervention for reducing cannabis use among non-college young adults (YAs) engaging in frequent or high-intensity cannabis use. The key products and services to be delivered through this 3-year project include: 1) Development of the "TAKE 5" intervention using focus groups...

CHARACTERIZING PROXIMAL RISK FOR DEPRESSIVE SYMPTOMS AND SUICIDAL IDEATION WITH ACUTE CANNABIS USE AND WITHDRAWAL AMONG ADOLESCENTS USING ECOLOGICAL MOMENTARY ASSESSMENT - PROJECT SUMMARY/ABSTRACT ADOLESCENCE IS THE PERIOD OF HIGHEST RISK FOR THE INITIATION AND ESCALATION OF CANNABIS USE AND EMERGENCE OF CO- MORBID PSYCHOPATHOLOGY, INCLUDING DEPRESSION AND SUICIDAL IDEATION (SI). CROSS-SECTIONAL AND PROSPECTIVE STUDIES HAVE FOUND THAT CANNABIS CO-OCCURS WITH DEPRESSION AND SI AT ALARMINGLY HIGH RATES. HOWEVER, THESE DISTAL ASSOCIATIONS DO NOT EXPLAIN HOW CHANGES IN CANNABIS USE IMPACT INTENSITY AND VARIABILITY IN DEPRESSIVE SYMPTOMS AND SI OVER SHORTER, CLINICALLY RELEVANT PERIODS OF TIME (E.G., DAYS, WEEKS, MONTHS), INCLUDING DURING INTOXICATION AND WITHDRAWAL. UNDERSTANDING THESE PROXIMAL RELATIONSHIPS WILL INFORM THE MECHANISMS THAT REINFORCE CANNABIS USE IN ADOLESCENTS AT HIGH RISK FOR DEPRESSION AND SUICIDE, YIELD ACTIONABLE INFORMATION ABOUT THE SPECIFIC MOMENTS DURING INTOXICATION AND WITHDRAWAL WHEN A USER WILL BE AT HIGHEST RISK FOR INCREASED INTENSITY AND VOLATILITY OF NEGATIVE MOOD AND SI, AND GUIDE CLINICAL DECISION-MAKING ON THE POTENTIAL THERAPEUTIC EFFECT OF SUSTAINED CANNABIS ABSTINENCE ON DEPRESSION AND SI. WE PROPOSE TO CONDUCT A 10-WEEK, MULTI- METHOD, RANDOMIZED STUDY, AND WILL RECRUIT 200 SCHOOL-BASED ADOLESCENTS, AGES 12-18 YEARS, WITH DAILY OR NEAR DAILY CANNABIS USE, CURRENT DEPRESSION, AND PAST MONTH SI. PARTICIPANTS WILL COMPLETE 2 WEEKS OF REAL-TIME, AMBULATORY SMARTPHONE MONITORING (ECOLOGICAL MOMENTARY ASSESSMENT; EMA) DURING BASELINE CANNABIS USE TO QUANTIFY THE TEMPORAL RELATIONSHIP BETWEEN USE AND MOOD AND SI, AND THE WITHIN-SUBJECT (E.G., CONCURRENT OTHER SUBSTANCE USE, SOCIAL CONTEXT OF USE) AND BETWEEN-SUBJECT (E.G., AVERAGE SEVERITY OF CANNABIS USE, DEPRESSION AND SI) FACTORS THAT MAY MODERATE THESE LINKAGES. TO DETERMINE HOW DEPRESSION AND SI CHANGE ACROSS SHORT- AND LONGER-TERM CANNABIS WITHDRAWAL, PARTICIPANTS WILL THEN BE RANDOMIZED TO 8 WEEKS OF MONITORING (CB-MON) OR ABSTINENCE INCENTIVIZED VIA CONTINGENCY MANAGEMENT (CB-ABST), AND WILL COMPLETE A 1-WEEK PHASE OF EMA AT WEEKS 1 AND 8 POST-RANDOMIZATION. THE OVERARCHING AIMS OF THIS PROPOSAL ARE TO TEST IF NEGATIVE MOOD AND SI ARE TEMPORARILY RELIEVED AND STABILIZED THROUGH ACUTE CANNABIS USE (I.E., CYCLE OF NEGATIVE REINFORCEMENT) AND TO TEST IF NEGATIVE MOOD AND SI DECREASE IN OVERALL (MEAN) LEVELS AND VARIABILITY AFTER CANNABIS WASH-OUT. THESE AIMS CAN BE UNIQUELY ACHIEVED USING EMA VIA SMARTPHONES, WHICH ENABLES HIGH-RESOLUTION, WITHIN-SUBJECTS DATA COLLECTION, THUS ALLOWING FOR ELUCIDATION OF THE SPECIFIC TEMPORAL RELATIONSHIPS BETWEEN CANNABIS USE/INTOXICATION AND WITHDRAWAL, AND DEPRESSIVE SYMPTOMS AND SI. THIS WILL IMPROVE ON EXISTING DATA DUE TO ITS HIGH ECOLOGICAL VALIDITY, PROSPECTIVE REPORTING, AND ABILITY TO COLLECT DYNAMIC, TIME-SPECIFIC CHANGES IN THE PERIODS IMMEDIATELY BEFORE, DURING, AND AFTER ACUTE CANNABIS INTOXICATION, AS WELL AS ACROSS THE COURSE OF WITHDRAWAL. PARTICULARLY WITH WIDESPREAD CANNABIS LEGALIZATION, WHICH WILL LIKELY BRING GREATER DRUG AVAILABILITY AND ENHANCED SOCIETAL ACCEPTANCE, THERE IS A GREAT NEED TO IMPROVE OUR UNDERSTANDING OF WHETHER, WHEN, AND AMONG WHOM CANNABIS USE PORTENDS HEIGHTENED RISK FOR PSYCHIATRIC ILLNESS, AND DEPRESSION AND SUICIDAL THOUGHTS AND BEHAVIORS IN PARTICULAR.

Posted 6/21/24